XOMA Corporation logo
XOMA Corporation XOMA
$ 30.47 -0.2%

Annual report 2025
added 03-18-2026

report update icon

XOMA Corporation Balance Sheet 2011-2026 | XOMA

Annual Balance Sheet XOMA Corporation

2025 2024 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

16 M 5.67 M -95.1 M -58.7 M -24.4 M -23.3 M -28.9 M 17.4 M -17.1 M -42.9 M -60.7 M -4.3 M -14.8 M

Long Term Debt

96.5 M 107 M 119 M - 34 K 12.8 M 27.1 M 21.7 M 14.6 M 25.3 M 42.8 M 16.3 M 35.2 M 37.7 M 33.5 M

Long Term Debt Current

2.46 M 446 K 54 K 34 K 195 K 179 K 163 K 789 K - 17.9 M 5.91 M 19.2 M 5.84 M 3.39 M 2.8 M

Total Non Current Liabilities

- - - - - 26.6 M 42.9 M 39.3 M 31.7 M 43.4 M 53.9 M 50.1 M 109 M 60.4 M 42 M

Total Current Liabilities

34.8 M 24.4 M 19.5 M 6.82 M 13 M 12.3 M 8.88 M 5.7 M 7.42 M 32.5 M 23.3 M 36.5 M 29.6 M 23.7 M 21 M

Total Liabilities

169 M 139 M 146 M 16.4 M 24.7 M 38.9 M 51.7 M 45 M 39.1 M 75.9 M 77.2 M 86.5 M 139 M 84.2 M 63 M

Deferred Revenue

- - - - - 1.45 M 1.89 M 1.29 M 1.41 M 899 K 3.2 M 1.09 M 2.22 M 3.41 M 5.7 M

Retained Earnings

-1.22 B -1.24 B -1.22 B -1.18 B -1.17 B -1.18 B -1.19 B -1.19 B -1.18 B -1.19 B -1.14 B -1.12 B -1.08 B -957 M -886 M

Total Assets

273 M 221 M 234 M 140 M 167 M 125 M 95.7 M 63.8 M 44.9 M 28.7 M 74.9 M 89.6 M 135 M 106 M 78 M

Cash and Cash Equivalents

82.9 M 102 M 153 M 57.8 M 93.3 M 84.2 M 56.7 M 45.8 M 43.5 M 25.7 M 65.8 M 78.4 M 102 M 45.3 M 48.3 M

Book Value

104 M 81.9 M 88.7 M 124 M 142 M 86.4 M 44 M 18.8 M 5.79 M -47.2 M -2.31 M 3.1 M -3.99 M 21.5 M 15 M

Total Shareholders Equity

83.9 M 61.9 M 88.7 M 124 M 142 M 86.4 M 44 M 18.8 M 5.79 M -47.2 M -2.31 M 3.1 M -3.99 M 21.5 M 15 M

All numbers in USD currency

Quarterly Balance Sheet XOMA Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

94.4 M 102 M 99.9 M 107 M 108 M 115 M - 119 M - - - - - - - 34 K 85 K 133 K 11.7 M 12.8 M 12.8 M 12.8 M 12.8 M 27.1 M 27.1 M 27.1 M 27.1 M 21.7 M 21.7 M 21.7 M 21.7 M 14.6 M 14.6 M 14.6 M 14.6 M 25.3 M 25.3 M 25.3 M 25.3 M 42.8 M 42.8 M 42.8 M 42.8 M 16.3 M 16.3 M 16.3 M 16.3 M 35.2 M 35.2 M 35.2 M 35.2 M 37.7 M 37.7 M 37.7 M 37.7 M 33.5 M 33.5 M 33.5 M 33.5 M

Total Liabilities

155 M 131 M 128 M 139 M 139 M 143 M - 146 M 18.1 M 15.5 M 19.1 M 16.4 M 15.8 M - 19.2 M 24.7 M 18.9 M 19.2 M 38.2 M 38.9 M 38.9 M 38.9 M 38.9 M 51.7 M 51.7 M 51.7 M 51.7 M 45 M 45 M 45 M 45 M 39.1 M 39.1 M 39.1 M 39.1 M 75.9 M 75.9 M 75.9 M 75.9 M 77.2 M 77.2 M 77.2 M 77.2 M 86.3 M 86.3 M 86.3 M 86.3 M 139 M 139 M 139 M 139 M 84.2 M 84.2 M 84.2 M 84.2 M 63 M 63 M 63 M 63 M

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - 798 K 798 K 798 K 798 K 798 K 851 K 595 K 490 K 1.12 M 171 K 490 K 615 K 615 K 615 K 615 K 899 K 899 K 899 K 899 K 3.2 M 3.2 M 3.2 M 3.2 M 1.09 M 1.09 M 1.09 M 1.09 M 2.22 M 2.22 M 2.22 M 2.22 M 3.41 M 3.41 M 3.41 M 3.41 M 5.7 M 5.7 M 5.7 M 5.7 M

Retained Earnings

-1.21 B -1.23 B -1.24 B -1.24 B -1.23 B -1.22 B - -1.22 B -1.2 B -1.2 B -1.19 B -1.18 B -1.18 B - -1.17 B -1.17 B -1.2 B -1.19 B -1.19 B -1.18 B -1.18 B -1.18 B -1.18 B -1.19 B -1.19 B -1.19 B -1.19 B -1.19 B -1.19 B -1.19 B -1.19 B -1.18 B -1.18 B -1.18 B -1.18 B -1.19 B -1.19 B -1.19 B -1.19 B -1.14 B -1.14 B -1.14 B -1.14 B -1.12 B -1.12 B -1.12 B -1.12 B -1.08 B -1.08 B -1.08 B -1.08 B -957 M -957 M -957 M -957 M -886 M -886 M -886 M -886 M

Total Assets

263 M 223 M 213 M 221 M 223 M 243 M - 234 M 124 M 126 M 134 M 140 M 146 M - 159 M 167 M 131 M 136 M 120 M 125 M 125 M 125 M 125 M 95.7 M 95.7 M 95.7 M 95.7 M 63.8 M 63.8 M 63.8 M 63.8 M 44.9 M 44.9 M 44.9 M 44.9 M 28.7 M 28.7 M 28.7 M 28.7 M 74.9 M 74.9 M 74.9 M 74.9 M 89.4 M 89.4 M 89.4 M 89.4 M 135 M 135 M 135 M 135 M 106 M 106 M 106 M 106 M 78 M 78 M 78 M 78 M

Cash and Cash Equivalents

45.2 M 75.1 M 90.3 M 102 M 147 M 150 M 142 M 153 M 33.5 M 31.4 M 44.3 M 57.8 M 78.3 M 83.2 M 88.6 M 93.3 M 72.2 M 78.9 M 67.8 M 84.2 M 84.2 M 84.2 M 84.2 M 56.7 M 56.7 M 56.7 M 56.7 M 45.8 M 28.4 M 38.7 M 42 M 43.5 M 43.5 M 43.5 M 43.5 M 25.7 M 25.7 M 25.7 M 25.7 M 65.8 M 65.8 M 65.8 M 65.8 M 78.4 M 78.4 M 78.4 M 78.4 M 102 M 102 M 102 M 102 M 45.3 M 45.3 M 45.3 M 45.3 M 48.3 M 48.3 M 48.3 M 48.3 M

Book Value

108 M 92.5 M 84.6 M 81.9 M 84.8 M 100 M - 88.7 M 106 M 110 M 115 M 124 M 130 M - 140 M 142 M 112 M 117 M 81.7 M 86.4 M 86.4 M 86.4 M 86.4 M 44 M 44 M 44 M 44 M 18.8 M 18.8 M 18.8 M 18.8 M 5.79 M 5.79 M 5.79 M 5.79 M -47.2 M -47.2 M -47.2 M -47.2 M -2.31 M -2.31 M -2.31 M -2.31 M 3.1 M 3.1 M 3.1 M 3.1 M -3.99 M -3.99 M -3.99 M -3.99 M 21.5 M 21.5 M 21.5 M 21.5 M 15 M 15 M 15 M 15 M

Total Shareholders Equity

87.9 M 72.4 M 84.6 M 61.9 M 64.8 M 80 M 82.3 M 88.7 M 106 M 110 M 115 M 124 M 130 M 135 M 140 M 142 M 112 M 117 M 81.7 M 86.4 M 86.4 M 86.4 M 86.4 M 44 M 44 M 44 M 44 M 18.8 M 18.8 M 18.8 M 18.8 M 5.79 M 5.79 M 5.79 M 5.79 M -47.2 M -47.2 M -47.2 M -47.2 M -2.31 M -2.31 M -2.31 M -2.31 M 3.1 M 3.1 M 3.1 M 3.1 M -3.99 M -3.99 M -3.99 M -3.99 M 21.5 M 21.5 M 21.5 M 21.5 M 15 M 15 M 15 M 15 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of XOMA Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Veracyte Veracyte
VCYT
$ 31.01 -5.46 % $ 2.44 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Vir Biotechnology Vir Biotechnology
VIR
$ 8.47 -5.47 % $ 1.17 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 32.67 -4.61 % $ 3.68 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 27.39 -2.87 % $ 2.79 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 437.99 -3.47 % $ 112 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Verastem Verastem
VSTM
$ 5.01 -5.29 % $ 347 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.56 -7.23 % $ 17.3 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 12.88 -7.74 % $ 1.95 B usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
$ 38.69 2.35 % $ 152 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 3.97 -4.0 % $ 233 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 320.49 -2.34 % $ 42 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.07 -1.82 % $ 21.9 M israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Equillium Equillium
EQ
$ 1.93 -6.31 % $ 111 M usaUSA
Amgen Amgen
AMGN
$ 351.01 -0.61 % $ 189 B usaUSA